Applying this therapeutically, they showed enzalutamide followed by the combination of enzalutamide and olaparib (a PARP inhibitor), induced cell death caused by DNA damage, and prevented clonal PCa cell proliferation.184. This evidence concerns the gene PARP1 and posterior cortical atrophy.